Who Benefits From 5 Years of Extended Endocrine Therapy? Who Benefits From 5 Years of Extended Endocrine Therapy?

MammaPrint genomic testing suggests that only patients with low-risk, not ultra-low-risk or high-risk, breast cancer benefit from 5 years of extended endocrine therapy.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news